Table 1.
Characteristics of the studied groups
| Number of patients | ccfDNA (ALU115) median (range), (ng/μL) | P-value | Integrity (ALU247/ALU115) | P-value | |
|---|---|---|---|---|---|
| PCa | 30 | 51.03±10.15a | <0.001 | 0.35±0.050 | <0.001 |
| Age (years) | |||||
| 63.73±8.09 | – | – | 0.231 | – | – |
| tPSA (ng/mL) | |||||
| <4 | 6 | 68.30±41.36a | 0.024 | 0.33±0.05 | 0.737 |
| >4 | 24 | 46.71±8.09a | 0.35±0.05 | ||
| Gleason score | |||||
| <6 | 15 | 52.48±35.51a | 0.723 | 0.34±0.05 | 0.724 |
| 7 | 8 | 38.60±8.25a | 0.36±0.05 | ||
| 8–10 | 7 | 62.11±12.11a | 0.36±0.05 | ||
| Metastatic | |||||
| Yes | 10 | 98.68±24.81 | <0.001 | 0.36±0.06 | 0.016 |
| No | 20 | 27.20±3.69 | 0.34±0.04 | ||
| BPH | 40 | 13.50±4.40 | 0.836* | 0.16±0.049 | 0.053 |
| Age (years) | |||||
| 60.80±8.14 | – | – | 0.231 | – | – |
| tPSA (ng/mL) | |||||
| <4 | 28 | 12.07±3.56 | 0.083 | 0.15±0.04 | 0.091 |
| >4 | 12 | 16.83±4.49 | 0.18±0.05 | ||
| Healthy subjects | 30 | 9.28±1.51 | 0.13±0.02 | ||
| Age (years) | |||||
| 60.63±7.69 | – | – | 0.231 | – | – |
| tPSA (ng/mL) | |||||
| <4 | 30 | – | – | – | – |
| >4 | – | ||||
Notes: aSE; *correlation between BPH group and healthy group.
Abbreviations: BPH, benign prostate hypertrophy; tPSA, total prostate-specific antigen; ccfDNA, circulation cell-free DNA; PCa, prostate cancer.